Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MorphoSys Achieves HuCAL Clinical Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

MorphoSys Achieves HuCAL Clinical Milestone

MorphoSys AG will receive a milestone payment from Centocor Ortho Biotech, Inc. for the initiation of a Phase I trial using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MorphoSys AG will receive a milestone payment from Centocor Ortho Biotech, Inc. for the initiation of a Phase I trial using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation.

“The advancement of a new HuCAL antibody into human clinical trials is an important step forward for MorphoSys,” commented Dr. Simon Moroney, chief executive officer of MorphoSys. “Progress in the development of innovative biopharmaceutical agents by our partners is a key driver of our company’s growth.”

This is the second HuCAL antibody program derived from the companies’ collaboration to enter clinical trials. With the new study, Centocor Ortho Biotech will be running three clinical trials of HuCAL antibodies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics